Current and future priorities for the development of optimal HIV drugs

Marco Vitoria, Ajay Rangaraj, Nathan Ford, Meg Doherty

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: To summarize global efforts to accelerate access to simpler, safer and more affordable antiretroviral drugs and how this has shaped HIV treatment policy over the last decade, and outline future priorities. Several expert consultations aimed at aligning opportunities for optimization of antiretroviral drugs have been convened by WHO in partnership with academic institutions, international agencies, innovators and manufacturers. The increased access to lifelong treatment for people living with HIV also brings about new challenges in the long-term use of antiretrovirals (ARVs). RECENT FINDINGS: The article describes the evolution of global research agenda on ARV optimization ascribing the characteristics of a target product profile, the importance of sequencing of first-line and second-line regimens, the role of programmatic data when looking at policy transition for new ARVs, inclusion of more subpopulations living with HIV, as well as the challenges in identifying what improvements can be made in an era where drugs are already safe, tolerable and efficacious. SUMMARY: Within a framework of evolving treatment harmonization and simplification, future therapeutic options in development must take into consideration safety and efficacy across a range of patient populations as well the mode of administration in the context of lifelong therapy.

Original languageEnglish (US)
Pages (from-to)143-149
Number of pages7
JournalCurrent Opinion in HIV and AIDS
Volume14
Issue number2
DOIs
StatePublished - Mar 1 2019

Fingerprint

HIV
Pharmaceutical Preparations
International Agencies
Therapeutics
Referral and Consultation
Safety
Research
Population

ASJC Scopus subject areas

  • Immunology
  • Hematology
  • Oncology
  • Oncology(nursing)
  • Infectious Diseases
  • Virology

Cite this

Current and future priorities for the development of optimal HIV drugs. / Vitoria, Marco; Rangaraj, Ajay; Ford, Nathan; Doherty, Meg.

In: Current Opinion in HIV and AIDS, Vol. 14, No. 2, 01.03.2019, p. 143-149.

Research output: Contribution to journalArticle

Vitoria, Marco ; Rangaraj, Ajay ; Ford, Nathan ; Doherty, Meg. / Current and future priorities for the development of optimal HIV drugs. In: Current Opinion in HIV and AIDS. 2019 ; Vol. 14, No. 2. pp. 143-149.
@article{c8a4c3effba649e79d404cda9a4e61ca,
title = "Current and future priorities for the development of optimal HIV drugs",
abstract = "PURPOSE OF REVIEW: To summarize global efforts to accelerate access to simpler, safer and more affordable antiretroviral drugs and how this has shaped HIV treatment policy over the last decade, and outline future priorities. Several expert consultations aimed at aligning opportunities for optimization of antiretroviral drugs have been convened by WHO in partnership with academic institutions, international agencies, innovators and manufacturers. The increased access to lifelong treatment for people living with HIV also brings about new challenges in the long-term use of antiretrovirals (ARVs). RECENT FINDINGS: The article describes the evolution of global research agenda on ARV optimization ascribing the characteristics of a target product profile, the importance of sequencing of first-line and second-line regimens, the role of programmatic data when looking at policy transition for new ARVs, inclusion of more subpopulations living with HIV, as well as the challenges in identifying what improvements can be made in an era where drugs are already safe, tolerable and efficacious. SUMMARY: Within a framework of evolving treatment harmonization and simplification, future therapeutic options in development must take into consideration safety and efficacy across a range of patient populations as well the mode of administration in the context of lifelong therapy.",
author = "Marco Vitoria and Ajay Rangaraj and Nathan Ford and Meg Doherty",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/COH.0000000000000527",
language = "English (US)",
volume = "14",
pages = "143--149",
journal = "Current Opinion in HIV and AIDS",
issn = "1746-630X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Current and future priorities for the development of optimal HIV drugs

AU - Vitoria, Marco

AU - Rangaraj, Ajay

AU - Ford, Nathan

AU - Doherty, Meg

PY - 2019/3/1

Y1 - 2019/3/1

N2 - PURPOSE OF REVIEW: To summarize global efforts to accelerate access to simpler, safer and more affordable antiretroviral drugs and how this has shaped HIV treatment policy over the last decade, and outline future priorities. Several expert consultations aimed at aligning opportunities for optimization of antiretroviral drugs have been convened by WHO in partnership with academic institutions, international agencies, innovators and manufacturers. The increased access to lifelong treatment for people living with HIV also brings about new challenges in the long-term use of antiretrovirals (ARVs). RECENT FINDINGS: The article describes the evolution of global research agenda on ARV optimization ascribing the characteristics of a target product profile, the importance of sequencing of first-line and second-line regimens, the role of programmatic data when looking at policy transition for new ARVs, inclusion of more subpopulations living with HIV, as well as the challenges in identifying what improvements can be made in an era where drugs are already safe, tolerable and efficacious. SUMMARY: Within a framework of evolving treatment harmonization and simplification, future therapeutic options in development must take into consideration safety and efficacy across a range of patient populations as well the mode of administration in the context of lifelong therapy.

AB - PURPOSE OF REVIEW: To summarize global efforts to accelerate access to simpler, safer and more affordable antiretroviral drugs and how this has shaped HIV treatment policy over the last decade, and outline future priorities. Several expert consultations aimed at aligning opportunities for optimization of antiretroviral drugs have been convened by WHO in partnership with academic institutions, international agencies, innovators and manufacturers. The increased access to lifelong treatment for people living with HIV also brings about new challenges in the long-term use of antiretrovirals (ARVs). RECENT FINDINGS: The article describes the evolution of global research agenda on ARV optimization ascribing the characteristics of a target product profile, the importance of sequencing of first-line and second-line regimens, the role of programmatic data when looking at policy transition for new ARVs, inclusion of more subpopulations living with HIV, as well as the challenges in identifying what improvements can be made in an era where drugs are already safe, tolerable and efficacious. SUMMARY: Within a framework of evolving treatment harmonization and simplification, future therapeutic options in development must take into consideration safety and efficacy across a range of patient populations as well the mode of administration in the context of lifelong therapy.

UR - http://www.scopus.com/inward/record.url?scp=85060917925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060917925&partnerID=8YFLogxK

U2 - 10.1097/COH.0000000000000527

DO - 10.1097/COH.0000000000000527

M3 - Article

C2 - 30562177

AN - SCOPUS:85060917925

VL - 14

SP - 143

EP - 149

JO - Current Opinion in HIV and AIDS

JF - Current Opinion in HIV and AIDS

SN - 1746-630X

IS - 2

ER -